Analysis of duration of response in oncology trials

Contemporary Clinical Trials

Volumn 29, Issue 4, 2008, Pages 456-465

  Ellis, Stuart ^a   Carroll, Kevin J ^b   Pemberton, Kristine ^b  

^a CMOs Office ^*  (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Duration of response (DoR); Expected DoR (EDoR); Probability of being in response function (PBRF)

Indexed keywords

ARTICLE; BIOSTATISTICS; CANCER RESEARCH; CLINICAL RESEARCH; PREDICTION; RANDOMIZATION; STATISTICAL ANALYSIS; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; CYTOTOXINS; DATA INTERPRETATION, STATISTICAL; HUMANS; MODELS, THEORETICAL; NEOPLASMS; PROGNOSIS; QUINAZOLINES; TIME FACTORS; TREATMENT OUTCOME;

EID: 44149125985     PISSN: 15517144     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cct.2007.10.008     Document Type: Article

References (12)

1. Therasse P., Arbuck S., Eisenhauer E., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92 (2000) 205-216
2. FDA. Oncologic drugs advisory committee meeting proceedings (March 12-13, 2003). http://www.fda.gov/ohrms/dockets/ac/cder03.html#OncologicDrugs http://www.fda.gov/ohrms/dockets/ac/cder03.html#OncologicDrugs
3. Guidance for Industry Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics (2007). http://www.fda.gov/cder/guidance/7478fnl.pdf http://www.fda.gov/cder/guidance/7478fnl.pdf
4. Johnson J., Williams G., and Pazdur R. End points and United States Food and Drug Administration, approval of oncology drugs. J Clin Oncol 21 (2003) 1404-1411
5. CHMP. Guideline on the evaluation of anticancer medicinal products in man (December 2005). http://www.emea.eu.int/pdfs/human/ewp/020595en.pdf London http://www.emea.eu.int/pdfs/human/ewp/020595en.pdf
6. Schroder T., and Schumaker M. Methodoligical. Problems in evaluating duration of response to therapy in cancer clinical trials. Onkologie 20 (1997) 393-399
7. CHMP. Points to consider on adjustment for baseline covariates (May 2003). http://www.emea.eu.int/pdfs/human/ewp/286399en.pdf London http://www.emea.eu.int/pdfs/human/ewp/286399en.pdf
8. Temkin N.R. An analysis for transient states with application to tumour shrinkage. Biometrics 34 (1978) 571-580
9. Begg B.B., and Larson M. A study of the use of the Probability-of-being-in-response function as a summary of Tumour response data. Biometrics 38 (1982) 59-66
10. Westfall P., and Young S. Resampling based multiple testing: examples and methods for p-value adjustment (1993), Wiley, New York
11. SAS/STAT User's Guide. 4th ed. vol. 2 (1989), SAS Institute Inc., Cary, NC Version 6
12. Herbst R.S., Giaccone G., Schiller J.S., et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial- INTACT 2. J Clin Oncol 22 (2004) 785-794